Do European patients with peripeheral arterial disease receive optimal lipid lowering therapy and achieve LDL-C goals? Results from the DA VINCI study
ON DEMAND
Speaker:
Session title: Risk Factors and Prevention ePosters
Topic: Lipids: Drug therapy
Session type: ePosters
Available from:

View abstract
Authors

KK Ray1 , M Feudjo Tepie2 , AL Catapano3 , P Giovas4 , S Bray5 , L Masana6 , N Weiss7 , N Poulter1 , 1Imperial College London - London - United Kingdom of Great Britain & Northern Ireland , 2Amgen UK Ltd - Uxbridge - United Kingdom of Great Britain & Northern Ireland , 3University of Milan and IRCCS Multimedica - Milan - Italy , 4Amgen (Europe) GmbH - Rotkreuz - Switzerland , 5Amgen UK Ltd - Cambridge - United Kingdom of Great Britain & Northern Ireland , 6University Hospital “Sant Joan”, Universitat Rovira i Virgili, IISPV.CIBERDEM - Reus - Spain , 7University Hospital "Carl Gustav Carus", Technische Universität Dresden - Dresden - Germany ,

Abstract

On behalf: The DA VINCI Investigators

Citation: N/A

Background: 2016 and 2019 EAS/ESC dyslipidemia guidelines recommend lipid lowering therapy (LLT) to reduce LDL-C in patients with peripheral arterial disease (PAD) with or without established cardiovascular (CV) disease, and recommend target LDL-C goals based on individual CV risk. Data regarding the implementation of these guidelines in clinical practice across Europe is currently lacking.

Purpose:  Describe LLT and achievement of the target LDL-C goals recommended in EAS/ESC dyslipidemia guidelines in patients with PAD.

Methods: The cross-sectional Da Vinci study enrolled consenting adults who had received LLT in the 12 months prior to the study visit and had at least one LDL-C measurement in the 14 months prior to the study visit, seen in a primary or secondary care setting across 18 European countries. Patients with coronary, peripheral and cerebral disease were enrolled at a ratio of 1:2:2. FH patients with prior CV events were excluded. Data were collected from medical records at a single visit between Jun ‘17–Nov ’18, including LLT and most recent LDL-C. Primary outcome was LDL-C goal attainment ≥ 28 days after starting most recent LLT (treatment-stabilised LLT).

Results: Of 5888 patients enrolled, 2794 met our definition of atherosclerotic cardiovascular disease (ASCVD). Of these ASCVD patients, 1036 (37%) had PAD. 31% (323/1036) of PAD patients were female and mean (SD) age was 69 (9.4) years. Concomitant CV risk factors included diabetes mellitus (473/1036 patients [46%]), hypertension (809/1036 [78%]) and smoking (794/1036 [77%]). 26% (271/1036) of patients with PAD also had coronary vascular disease and 12% (122/1036) also had cerebrovascular disease. At the visit date, approximately half (497/1036 [48%]) of all PAD patients were receiving moderate intensity statins and 41% (421/1036) were receiving high intensity statins. 818 (73%) of the PAD patients had a treatment-stabilised LDL-C measurement (median, 2.20 mmol/L), of whom 40% (326/818) achieved the 2016 EAS/ESC LDL-C goal of 1.8 mmol/L and only 19% (159/818) achieved the 2019 goal of 1.4mmol/L.

Conclusions European patients with PAD are not treated as per EAS/ESC recommendations, with a large proportion receiving suboptimal LLT and fewer than half achieving target LDL-C levels.